INCY

Incyte Corporation

64.02 USD
-0.23 (-0.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Incyte Corporation stock is up 2.12% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 51.61% of the previous 30 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 10 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Jun 17:49 21 Jun, 2024 65.00 CALL 810 177
13 Jun 18:31 20 Sep, 2024 65.00 CALL 94 189
13 Jun 18:34 20 Sep, 2024 65.00 CALL 146 189
13 Jun 19:33 21 Jun, 2024 50.00 CALL 45 29
14 Jun 13:53 19 Jul, 2024 62.50 CALL 1000 39
14 Jun 13:55 20 Sep, 2024 60.00 CALL 107 487
14 Jun 15:16 19 Jul, 2024 60.00 CALL 100 579
17 Jun 13:37 19 Jul, 2024 60.00 CALL 499 683
17 Jun 18:35 21 Jun, 2024 55.00 CALL 265 3349
24 Jun 19:38 20 Dec, 2024 70.00 CALL 152 15

About Incyte Corporation

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

  • BMO Capital
    Tue Jul 2, 05:14
    sell
    downgrade
  • Cantor Fitzgerald
    Tue Jun 18, 09:45
    hold
    confirm